|
| Press Releases |
|
 |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
| Wednesday, February 19, 2025 |
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook |
| Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL). more info >> |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
| Tuesday, December 17, 2024 |
|
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC. more info >> |
|
| Thursday, December 12, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. more info >> |
|
| Wednesday, December 11, 2024 |
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership |
| As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise. more info >> |
|
| Wednesday, December 4, 2024 |
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy |
| Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Toni Bou Wins 19th Consecutive FIM Trial World Championship Title
Sept 8, 2025 18:53 JST
|
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 
Sept 8, 2025 17:49 JST
|
|
|
Honda to Commercialize UNI-ONE Hands-Free Personal Mobility Device
Sept 8, 2025 15:56 JST
|
|
|
European Dairy Exports from Ireland to Asia Top EUR440 Million in 2024 as Ireland Launches EUR3.2 Million EU Campaign to Strengthen Partnerships
Sept 8, 2025 14:49 HKT/SGT
|
|
|
Mitsubishi Power Signs Contract to Supply Two M701JAC Gas Turbines to O Mon 4 Power Plant
Sept 8, 2025 15:36 JST
|
|
|
Fujitsu develops generative AI reconstruction technology for optimized and energy-efficient AI models based on Takane LLM
Sept 8, 2025 14:28 JST
|
|
|
Yuexiu REIT Disposes of 50% Interest in Yuexiu Financial Tower in Guangzhou and Reorganises the Remaining 50%
Sept 8, 2025 08:02 HKT/SGT
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME end on a high note
Sept 7, 2025 13:13 HKT/SGT
|
|
|
10th anniversary CENTRESTAGE concludes successfully
Sept 6, 2025 21:36 JST
|
|
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure
Sept 5, 2025 21:00 JST
|
|
|
Fourth Paradigm announces 2025 interim results
Sept 5, 2025 18:25 HKT/SGT
|
|
|
Asia Unicorn Forum Releases 2024 Report: China, India, Israel Top Asian Unicorn Rankings
Sept 5, 2025 11:03 HKT/SGT
|
|
|
CBL International Reports 1H 2025 Results Highlighting Strong Biofuel Growth, Reduced Net Loss, and Improved Gross Profit Margin
Sept 5, 2025 10:36 HKT/SGT
|
|
|
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sept 5, 2025 11:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
